ZFIN Image: Gribble et al., 2007, Fig. 5

Image

Figure Caption

Fig. 5 Analysis patterning defects in 4-(diethylamino)-benzaldehyde (DEAB) -treated embryos. A,B: Dorsal view of 24 hours postfertilization (hpf) embryos showing krox20 mRNA expression. Dimethyl sulfoxide (DMSO) -treated embryos show krox20 expression in rhombomeres 3 and 5 and DEAB-treated embryos only show expression in rhombomere 3. C,D: dorsal view of green fluorescent protein (GFP) expression in cranial nuclei in Tg(isl1:GFP)^rw0 embryos at 24 hpf. DMSO-treated embryos have normal GFP expression, and DEAB-treated embryos have loss of the vagal (X) nuclei and abnormal positioning of the VIIIth cranial nuclei. E-P: Spinal cord cross-sections of embryos treated with DMSO or DEAB. dbx1a mRNA expression is unaffected when embryos are fixed at 18 hpf (E,F) but by 24 hpf, progenitor expression and often postmitotic neuron expression of dbx1a is lost (G,H). dbx1b expression is unaffected at 18 hpf (I,J) and 24 hpf (K,L) in DEAB-treated embryos. dbx2 expression is prematurely induced at 18 hpf in DEAB-treated embryos (M,N) and is maintained at 24 hpf (O,P).

Figure Data

Expression / Labeling details

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dev. Dyn.